Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model

2SLS versus 2SRI: Appropriate methods for rare outcomes and/or rare exposures

(2018) Anirban Basu et al.   HEALTH ECONOMICS

Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes

(2016) Suetonia C. Palmer et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

(2016) Steven P. Marso et al.   NEW ENGLAND JOURNAL OF MEDICINE

Medication adherence in patients with diabetes mellitus: does physician drug dispensing enhance quality of care? Evidence from a large health claims database in Switzerland

(2016) Carola A Huber et al.   Patient Preference and Adherence

Follow-up of Glycemic Control and Cardiovascular Outcomes in Type 2 Diabetes

(2015) Rodney A. Hayward et al.   NEW ENGLAND JOURNAL OF MEDICINE

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82

(2013) A. J. Hayes et al.   DIABETOLOGIA

Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Glycemic Targets and Cardiovascular Disease

(2008) William T. Cefalu   NEW ENGLAND JOURNAL OF MEDICINE

Glucose Control and Vascular Complications in Veterans with Type 2 Diabetes

(2008) William Duckworth et al.   NEW ENGLAND JOURNAL OF MEDICINE